Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors

Ítems similars

• Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance
  per: Lin, Liping, et al.
  Publicat: (2018)
• Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
  per: Lin, Liping, et al.
  Publicat: (2018)
• Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
  per: Lin, Liping, et al.
  Publicat: (2018)
• Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
  per: Lin, Liping, et al.
  Publicat: (2016)
• Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
  per: Kloth, J S L, et al.
  Publicat: (2015)